Buscar
Mostrando ítems 1-10 de 23
Pitfalls to avoid when using phage display for snake toxins
(2017-02)
Antivenoms against bites and stings from snakes, spiders, and scorpions are associated with immunological side effects and high cost of production, since these therapies are still derived from the serum of hyper-immunized ...
High-density peptide microarray exploration of the antibody response in a rabbit immunized with a neurotoxic venom fraction
(2017-11)
Polyvalent snakebite antivenoms derive their therapeutic success from the ability of their antibodies to
neutralize venom toxins across multiple snake species. This ability results from a production process
involving ...
Discovery and optimization of a broadly-neutralizing human antibody against long-chain α-neurotoxins from snakes
(2023-02-08)
Snakebite envenoming continues to claim many lives across the globe, necessitating the development of improved therapies. To this end, broadly-neutralizing human monoclonal antibodies may possess advantages over current ...
Novel snakebite therapeutics must be tested in appropriate rescue models to robustly assess their preclinical efficacy
(2020)
In the field of antivenom research, development, and manufacture, it is often advised to follow the World Health Organization’s (WHO) guidelines for the production, control, and regulation of snake antivenom immunoglobulins, ...
Antibody-dependent enhancement of toxicity of myotoxin II from Bothrops asper
(2024)
Improved therapies are needed against snakebite envenoming, which kills and
permanently disables thousands of people each year. Recently developed
neutralizing monoclonal antibodies against several snake toxins have ...
Cross-recognition of a pit viper (Crotalinae) polyspecific antivenom explored through high-density peptide microarray epitope mapping
(2017-07)
Snakebite antivenom is a 120 years old invention based on polyclonal mixtures of antibodies
purified from the blood of hyper-immunized animals. Knowledge on antibody recognition
sites (epitopes) on snake venom proteins ...
Selecting key toxins for focused development of elapid snake antivenoms and inhibitors guided by a Toxicity Score
(2015-09-15)
For more than 100 years, antivenoms have been produced by traditional methods of immunization of large mammals with mixtures of snake venoms (World Health Organization, 2010 and Gutiérrez et al., 2011). With the introduction ...
Danger in the reef: Proteome, toxicity, and neutralization of the venom of the olive sea snake, Aipysurus laevis
(2015-12-01)
Four specimens of the olive sea snake, Aipysurus laevis, were collected off the coast of Western Australia, and the venom proteome was characterized and quantitatively estimated by RP-HPLC, SDS-PAGE, and MALDI-TOF-TOF ...
Pros and cons of different therapeutic antibody formats for recombinant antivenom development
(2018-05)
Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many
advances in immunology, synthetic biology, and antibody research, different approaches and antibody
formats are being ...
In vivo neutralization of Myotoxin II, a phospholipase A2 homolog from Bothrops asper venom, using peptides discovered via phage display technology
(2022)
Many snake venom toxins cause local tissue damage in prey and victims, which constitutes an important pathology that is challenging to treat with existing antivenoms. One of the notorious toxins that causes such effects ...